NasdaqGM:CSTLHealthcare
Castle Biosciences (CSTL) Margin Miss Reinforces Concerns Over Unprofitable Growth and Sector Lag
Castle Biosciences (CSTL) continues to operate at a loss, with recent filings confirming the company has yet to achieve net profit margin improvement over the past year and is still generating negative earnings. Despite reducing its annual losses at a rate of 9.6% per year over the last five years, it remains on a slower growth path. Forecasted revenue is expected to rise 6.5% per year, lagging behind the broader US market’s 10.5% annual growth rate. With profitability still out of reach in...